Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Neoplasms 2Melanoma 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Recurrence 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Central Nervous System Neoplasms 1Brain Neoplasms 1Brain Diseases 1

Interventions

Magnetic Resonance Spectroscopy 6Specimen Handling 3Nivolumab 3Fluorodeoxyglucose F18 3Cisplatin 3Cetuximab 3ulixertinib 2tipifarnib 2selpercatinib 2binimetinib 2Trastuzumab 2Surveys and Questionnaires 2Radiotherapy 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2FAPI-46 2Disulfides 2Biopsy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Midazolam × CNS × Clear all
NCT05355701 2026-06-05

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡